| Oct 28 |
Sage Therapeutics Q3 2024 Earnings Preview
|
| Oct 23 |
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
|
| Oct 22 |
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
| Oct 18 |
State Street Corp's Strategic Acquisition of Sage Therapeutics Shares
|
| Oct 18 |
Sage Therapeutics to Reduce Workforce by 33%, Stock Down
|
| Oct 17 |
Sage lays off 55% of R&D workforce and refocuses pipeline
|
| Oct 17 |
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
|
| Oct 17 |
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
|
| Oct 17 |
Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
|
| Oct 17 |
Sage Therapeutics to lay off one-third staff under reorganization
|
